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 13 
ABSTRACT 14 
In the present study, the ethanolic extracts of fourteen edible mushrooms were investigated 15 
for their anti-inflammatory potential in LPS (lipopolysaccharide) activated RAW 264.7 16 
macrophages. Furthermore the extracts were chemically characterized in terms of phenolic 17 
acids and related compounds. The identified molecules (p-hydroxybenzoic, p-coumaric and 18 
cinnamic acids) and their glucuronated and methylated derivatives obtained by chemical 19 
synthesis were also evaluated for the same bioactivity, in order to establish structure-activity 20 
relationships and to comprehend the effects of in vivo metabolism reactions in the activity of 21 
the compounds. The extracts of Pleurotus ostreatus, Macrolepiota procera, Boletus impolitus 22 
and Agaricus bisporus revealed the strongest anti-inflammatory potential (EC50 values 96 ± 1 23 
to 190 ± 6 µg/mL, and also the highest concentration of cinnamic acid (656 to 156 µg/g), 24 
which was also the individual compound with the highest anti-inflammatory activity. The 25 
derivatives of p-coumaric acid revealed the strongest properties, specially the derivative 26 
methylated in the carboxylic group (CoA-M1) that exhibited similar activity to the one 27 
showed by dexamethaxone used as anti-inflammatory standard; by contrast, the derivatives of 28 
p-hydroxybenzoic revealed the lowest inhibition of NO production. All in all, whereas the 29 
conjugation reactions change the chemical structure of phenolic acids and may increase or 30 
decrease their activity, the glucuronated and methylated derivatives of the studied compounds 31 
are still displaying anti-inflammatory activity. 32 
 33 
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 36 
1. INTRODUCTION 37 
Inflammation is considered to be part of the complex biological response to remove injury or 38 
harmful stimuli such as pathogens, damaged cells, or irritation and this is a central feature of 39 
many pathophysiological conditions such as atherosclerosis, obesity, metabolic syndrome, 40 
diabetes (Pradhan, 2007) and even several types of cancers (Moro et al., 2012).  41 
When cells are exposed to immune stimulants, the pro-inflammatory cells, such as 42 
macrophages, monocytes, or other host cells, start to produce cytokines and other mediators, 43 
which initiate the inflammation process. Among the various inflammatory mediators, the 44 
most common are interleukins (IL-1β, IL-6, IL-8), tumour necrosis factor (TNF-α), nuclear 45 
factor-κB (NF-κB), intercellular adhesion molecule-1 (ICAM-1), inducible type 46 
cyclooxygenase-2 (COX-2), prostaglandin E2 (PGE2), 5-lipooxygenase (5-LOX), and 47 
inducible nitric oxide synthase (iNOS) that leads to the production of reactive nitrogen 48 
species such as nitric oxide (NO). Overproduction of these inflammatory mediators leads to 49 
different kinds of cell damage (Kanwar, Kanwar, Burrow, & Baratchi, 2009).  50 
Recently, the nonsteroidal anti-inflammatory drugs (NSAIDs) are usually the most 51 
commonly administered drugs to reduce inflammation in the body. Many studies, however, 52 
have shown that the long-term administration of NSAIDs has the potential for significant side 53 
effects on the gastrointestinal tract with numerous harmful effects such as mucosal lesions, 54 
bleeding, peptic ulcers, and intestinal perforation (Dugowson & Gnanashanmugam, 2006). 55 
Recent studies show that NSAIDs are also associated with a relatively high incidence of renal 56 
adverse drug reactions, nephrotic syndrome, high blood pressure, acute tubular necrosis and 57 
cardiovascular toxicity (Elsayed, Hesham, Mohammad, & Ramlan, 2014).  58 
As a result, research studies are now being channelled towards discovery of bioactive 59 
compounds with ability to suppress the production of inflammatory mediators. A good model 60 
to test potential anti-inflammatory drugs are macrophages, which are large specialized cells 61 
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that engulf and digest cellular debris, microbes or cancer cells in a process called 62 
phagocytosis. They play an important role in non-specific host defence mechanisms and help 63 
to initiate other defence mechanisms. Beyond stimulating the immune system, macrophages 64 
play a crucial role in the inflammatory response through the release of a variety of factors, 65 
such as NO, TNF-α, IL-1β, IL-6, in response to an activating stimulus, e.g. 66 
lipopolysaccharide (Moro et al., 2012). 67 
Mushrooms are widely appreciated all over the world not only for their culinary and 68 
nutritional properties (Kalac, 2009), but also for their pharmacological value as sources of 69 
important bioactive molecules, such as antioxidant (Puttaraju, Venkateshaiah, Dharmesh, 70 
Urs, & Somasundaram, 2006; Ferreira, Barros, & Abreu, 2009; Heleno, Martins, Queiroz, & 71 
Ferreira, 2015), antitumor (Moradali, Mostafavi, Ghods, & Hedjaroude, 2007; Ferreira, Vaz, 72 
Vasconcelos, & Martins, 2010, Carocho & Ferreira, 2013), antimicrobial (Alves, Ferreira, 73 
Dias, Teixeira, Martins, & Pintado, 2012; Alves, Ferreira, Froufe, Abreu, Martins, & Pintado, 74 
2013), immunomodulator (Borchers, Krishnamurthy, Keen, Meyers, & Gershwin, 2008), 75 
antiatherogenic (Mori, Kobayashi, Tomita, Inatomi, & Ikeda, 2008) and hypoglycemic 76 
compounds (Hu, Wang, Lien, Liaw, & Lee, 2006). Due to these properties, they have been 77 
recognized as functional foods, as well as valuable sources of natural medicines and 78 
nutraceuticals (Lindequist, Niedermeyer, Jülich, 2005; Guillamón et al., 2010).  79 
Moreover, mushrooms have also demonstrated some anti-inflammatory potential based on 80 
their ability to reduce the production of inflammatory mediators (Padilha, Avila, Sousa, 81 
Cardoso, Perazzo, & Carvalho, 2009; Elsayed et al., 2014). Previous research studies have 82 
been carried out on several mushroom species, mainly in methanolic and ethanolic extracts 83 
(Table 1). Different compounds have been pointed out as the responsible for the anti-84 
inflammatory activity such as β-glucans (Nosálóva, Bobek, Cerna, Galbavy, & Tvrtina, 85 
2001), triterpenes (Ma, Chen, Dong, & Lu, 2013), glycoproteins (Gunawardena et al., 2014) 86 
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and even phenolic compounds (Moro et al., 2012). However, not much is known about the 87 
phenolic bioactive forms in vivo; these compounds are metabolized and circulate in the 88 
organism as glucuronated, sulfated and methylated metabolites, displaying higher or lower 89 
bioactivity (Heleno et al., 2015).  90 
Therefore, the present study aimed to investigate the anti-inflammatory activity of selected 91 
mushroom species from the Northeast of Portugal, using ethanolic extracts in LPS activated 92 
RAW 264.7 macrophages. Furthermore, after characterization of the extracts in terms of 93 
phenolic acids and related compounds, the identified individual parent molecules and their 94 
synthesised glucuronated and methylated derivatives were evaluated for the same bioactivity, 95 
in order to establish structure-activity relationships. 96 
 97 
2. MATERIALS AND METHODS  98 
2.1. Mushroom species and extracts preparation 99 
Ten wild mushroom species (Amanita caesaria (Scop.) Pers., Boletus aereus Bull., B. edulis 100 
Bull., B. flagrans Vittad., B. impolitus Fr., B. reticulatus Schaeff., Cantharellus cibarius Fr., 101 
Lactarius deliciosus (L. ex Fr.) S.F. Gray, Macrolepiota procera (Scop.) Singer and 102 
Morchella esculenta Fr.), collected in the Northeast of Portugal, and four cultivated species 103 
(Agaricus bisporus (J.E. Lange) Emil J. Imbach, A. bisporus Portobello (J.E. Lange) Emil J. 104 
Imbach, Pleurotus eryngii (DC.) Quél. and Pleurotus. ostreatus (Jacq. ex Fr.) P. Kumm.) 105 
were used in the present study. All species were deposited in the herbarium of the School of 106 
Agriculture in Polytechnic Institute of Bragança, and were previously characterized by the 107 
research group in terms of nutritional value and chemical composition (including primary and 108 
secondary metabolites) (Barros, Dueñas, Ferreira, Baptista, & Santos-Buelga, 2009, 109 
Grangeia, Heleno, Barros, Martins, & Ferreira, 2011; Heleno, Barros, Sousa, Martins, Santos-110 
Buelga, & Ferreira., 2011; Reis et al., 2011; Pereira, Barros, Martins, & Ferreira, 2012; Reis, 111 
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Barros, Martins, & Ferreira, 2012; Heleno et al., 2013b). Their antioxidant, antimicrobial and 112 
antitumor properties were also previously evaluated by the group 113 
(http://esa.ipb.pt/biochemcore/index.php/studied-mushrooms). In the present work, the in 114 
vitro anti-inflammatory activity was evaluated in ethanolic extracts prepared as follows. 115 
Lyophilized (Ly-8-FM-ULE, Snijders, Holland) mushroom powder (20 mesh) of each species 116 
(0.5 g) was extracted with ethanol (15 mL), by maceration with stirring for 1 h. Then, the 117 
extract was filtered through Whatman no 4 filter paper and the extraction procedure was 118 
repeated one more time. The filtrate was rotary evaporated to remove ethanol and the 119 
extraction yield was calculated by measuring the extract weight. 120 
 121 
2.2. Reagents 122 
Acetonitrile 99.9% was of high-performance liquid chromatography (HPLC) grade from Lab-123 
Scan (Lisbon, Portugal). p-Hydroxybenzoic acid, p-coumaric acid, cinnamic acid, Dulbecco’s 124 
modified Eagle’s minimum essential medium (DMEM), fetal bovine serum (FBS), penicillin, 125 
streptomycin, Griess reagent system (Promega), DMSO, sulphorodamine B (SRB) and 126 
lipopolysaccharide (LPS) were obtained from Sigma-Aldrich Co. (Saint Louis, MO, USA). 127 
All other chemicals and solvents were of analytical grade and purchased from common 128 
suppliers. 129 
 130 
2.3. Chemical characterization of the extracts 131 
The dry mass of each mushroom extract was re-dissolved in water/ethanol (50:50, v/v) and 132 
filtered through a 0.22 µm nylon disposable filter for HPLC analysis. The analysis was 133 
performed using a Shimadzu 20A series ultra-fast liquid chromatograph (UFLC, Shimadzu 134 
Coperation, Kyoto, Japan). Separation was achieved on a Waters Spherisorb S3 ODS2 C18 135 
column (3 µm, 150 mm x 4.6 mm) column thermostatted at 35 ºC. The solvents used were: 136 
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(A) 0.1% formic acid in water, (B) acetonitrile. The elution gradient established was: 10% B 137 
to 15% B over 5 min, 15–25% B over 5 min, 25–35% B over 10 min, isocratic 50% B for 10 138 
min, and re-equilibration of the column, using a flow rate of 0.5 mL/min. Detection was 139 
carried out in a photodiode array detector (PDA), using 280 nm as the preferred wavelength. 140 
The phenolic acids (group of phenolic compounds identified in the samples) were quantified 141 
by comparison of the area of their peaks recorded at 280 nm with calibration curves obtained 142 
from commercial standards of each compound: protocatechuic acid (y = 164741x, R2=0.999), 143 
p-hydroxybenzoic acid (y = 113523x, R2=0.999), p-coumaric acid (y = 433521x, R2=0998) 144 
and cinnamic acid (y = 583527x, R2=0.998), 5 to 80 µg/mL. The results were expressed as µg 145 
per g of extract.  146 
 147 
2.4. Phenolic acids and synthesised derivatives 148 
p-Hydroxybenzoic acid, p-coumaric acid and cinnamic acid, identified in the mushroom 149 
extracts, were used as staring reagents for the synthesis of methylated and glucuronated 150 
derivatives of the identified compounds (Figure 1); these compounds were previously 151 
synthesized and completely characterized by the authors (Heleno et al., 2013a; Heleno et al., 152 
2014b). Briefly, the glucuronated derivatives (HA-GP, CoA-GP and CA-GP) were obtained 153 
by reacting the parent molecules with acetobromo-α-D-glucuronic acid methyl ester under 154 
argon and using DMSO (dimethylsulfoxide) as solvent at room temperature. The methylated 155 
derivatives (HA-M1, CoA-M1 and CA-M) were prepared using methanol and sulphuric acid 156 
at room temperature; HA-M2 and CoA-M2 were synthesised using dimethyl sulphate in 157 
acetone at room temperature. Finally, HA-M3 and CoA-M3 were obtained by the hydrolysis 158 
of compounds HA-M2 and CoA-M2 using ethanol at 65ºC and adjusting the pH to 3. All the 159 
synthesised compounds were fully characterized by 1H NMR, 13C NMR, HRMS (high 160 
resolution mass spectrometry) and melting point. 161 
 162 
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2.5. Evaluation of the anti-inflammatory activity  163 
2.5.1. Cells treatment  164 
The anti-inflammatory activity was carried out according to Moro et al. (2012) and García-165 
Lafuente et al. (2014) with some modifications. The mouse macrophage-like cell line RAW 166 
264.7 was cultured in DMEM medium supplemented with 10% heat-inactivated foetal bovine 167 
serum, glutamine and antibiotics at 37 °C under 5% CO2, in humidified air. For each 168 
experiment, cells were detached with a cell scraper. A cell density of 5 x 105 cells/mL was 169 
used, and the proportion of dead cells was less than 5%, according to Trypan blue dye 170 
exclusion test. 171 
Cells were seeded in 96-well plates at 150,000 cells/well and allowed do attach to the plate 172 
overnight. Then, cells were treated with the different concentrations of each one of the 173 
extracts for 1h. Dexamethasone (50 µM) was used as a positive control for the experiment. 174 
The following step was the stimulation with LPS (1 µg/mL) for 18h. The effect of all the 175 
tested samples in the absence of LPS was also evaluated, in order to observe if they induced 176 
changes in nitric oxide (NO) basal levels. In negative controls, no LPS was added. Both 177 
extracts and LPS were dissolved in supplemented DMEM.  178 
 179 
2.5.2. Nitric oxide determination 180 
Both the extracts, and the pure identified compounds and their synthezised derivatives were 181 
submitted to the anti-inflammatory activity assay. The ethanolic extracts were dissolved in 182 
water (non cytotoxic solvent) at 8 mg/mL, while the identified individual compounds and 183 
their synthesised methylated and glucuronated derivatives were dissolved in DMSO at 50% 184 
concentration in stock solutions. These solutions were then submitted to further dilutions 185 
(400 µg/mL to 50 µg/mL and 2500 µM to 39 µM, for the extracts and compounds, 186 
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respectively) in order to determine effective concentrations (Moro et al., 2012; García-187 
Lafuente et al., 2014). 188 
For the determination of nitric oxide, Griess Reagent System kit was used, which contains 189 
sulphanilamide, N-(1-napthyl)ethylenediamine hydrochloride (NED) and nitrite solutions. A 190 
reference curve of the nitrite (sodium nitrite 100 µM to 1.6 µM; y=0.0066x+0.1349; 191 
R2=0.9986) was prepared in a 96-well plate. The cell culture supernatant (100 µL) was 192 
transferred to the plate and mixed with Sulphanilamide and NED solutions, 5-10 minutes 193 
each, at room temperature. The nitric oxide produced was determined by measuring the 194 
absorbance at 540 nm (microplate reader ELX800 Biotek), and by comparison with the 195 
standard calibration curve.  196 
 197 
2.6. Statistical analysis 198 
For all the experiments three samples were analyzed and all the assays were carried out in 199 
triplicate. The results are expressed as mean values ± standard deviation (SD). The 200 
differences between the different samples were analyzed using one-way analysis of variance 201 
(ANOVA) followed by Tukey’s honestly significant difference post hoc test with α = 0.05, 202 
coupled with Welch’s statistic. This treatment was carried out using SPSS v. 22.0 program. 203 
 204 
3. RESULTS AND DISCUSSION 205 
3.1. Chemical characterization of the extracts 206 
Ethanolic extracts were prepared from fourteen different edible mushroom species: Agaricus 207 
bisporus, A. bisporus Portobello, Amanita caesaria, Boletus aereus, B. edulis, B. flagrans, B. 208 
impolitus, B. reticulatus, Cantharellus cibarius, Lactarius deliciosus, Macrolepiota procera, 209 
Pleurotus eryngii, Pleurotus ostreatus and Morchella esculenta. One phenolic acid (p-210 
hydroxybenzoic acid) and two cinnamic acids (p-coumaric and cinnamic acids) were detected 211 
by HPLC-PDA in the different extracts; their concentrations are presented in Table 2. The 212 
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phenolic composition of the mushrooms seems to be characterised by the presence of 213 
phenolic acids, being cinnamic acid the major compound in most cases. No peaks were found 214 
in the extracts whose UV spectra could be associated to hydroxycinnamic acids or their 215 
tartaric or quinic esters, nor were flavonoids found. The fact that no flavonoids were 216 
identified is not unexpected since, it is assumed that only plants possess the biosynthetic 217 
ability to produce flavonoids and not animals and fungi (Iwashina, 2000). Furthermore, these 218 
compounds have been extensively reported in mushroom species (Barros et al., 2009; Vaz et 219 
al., 2011).  220 
The three compounds were only identified and quantified in three of the analysed species, B. 221 
aereus, B. impolitus and P. ostreatus, while A. caesarea, C. cibarius and L. deliciosus 222 
presented p-hydroxybenzoic and cinnamic acids. The other mushroom samples only revealed 223 
the presence of cinnamic acid. P. ostreatus revealed the highest concentration of phenolic 224 
acids mainly due to the high contribution of cinnamic (619±3 µg/g) and p-hydroxybenzoic 225 
(295±5 µg/g) acids. M. procera and B. impolitus also presented high amounts of cinnamic 226 
acid (522 ± 1 µg/g and 505 ± 12 µg/g, respectively). The samples A. bisporus Portobello, B. 227 
edulis and B. flagrans revealed only the presence of cinnamic acid, but in very low 228 
concentration. Reis et al. (2011) and Heleno et al. (2013b) also reported the presence of 229 
protocatechuic acid in A. caesaria and M. esculenta, respectively, although they performed an 230 
extraction with methanol:water, while in the present study ethanolic extracts were prepared. 231 
Therefore, the different extraction conditions could be responsible for the dissimilarity 232 
observed in the phenolic profiles. 233 
 234 
3.2. In vitro anti-inflammatory activity of the extracts 235 
The effects of the ethanolic extracts on the production of inflammatory mediators (NO) in 236 
RAW 264.7 macrophages, upon stimulation with LPS, are shown in Figure 2. The results 237 
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indicate that most of the assayed extracts inhibited LPS-induced NO production in a dose-238 
dependent manner. For an easier comparison of the results, EC50 values were calculated 239 
based on 50% of inhibition of NO production (Table 3). The most efficient species was P. 240 
ostreatus (96 ± 1 µg/mL), followed by M. procera (162 ± 2 µg/mL), B. impolitus (166 ± 10 241 
µg/mL) and A. bisporus (190 ± 6 µg/mL). These results are in agreement with the reports by 242 
Moro et al. (2012) and Gunawardena et al. (2014) that described anti-inflammatory activity, 243 
by decreasing NO levels in RAW 264.7 cells, of ethanolic and methanolic extracts of A. 244 
bisporus, C. cibarius, L. deliciosus and P. ostreatus (Table 1). The ethanolic extracts from A. 245 
bisporus Portobello, B. edulis and B. flagrans appeared as the less active, showing EC50 246 
values above 400 µg/mL. Moro et al. (2012) reported some activity in the case of methanolic 247 
extracts of B. edulis with 10% inhibition of NO production at concentrations of 500 µg/mL. 248 
Although many substances may participate in the anti-inflammatory activity, phenolic 249 
compounds have been largely recognised as natural molecules with anti-inflammatory 250 
effects. Positive correlations have been found between phenolic compounds and anti-251 
inflammatory effects (Cheung, Cheung, & Ooi, 2003; Kim et al., 2008). In the present study, 252 
it was also observed that the extract with the highest anti-inflammatory activity showed the 253 
highest levels of cinnamic and phenolic acids.  254 
 255 
3.3. In vitro anti-inflammatory activity of the compounds identified in the extracts 256 
To demonstrate this supposition, the activity of the individual compounds present in the 257 
extracts were further evaluated (Table 4). Phenolic acids, and cinnamic acid, that are the 258 
main responsible molecules for the bioactivities exhibited by mushrooms are well known for 259 
their biological properties, mainly due to the OH groups present in their chemical structure, 260 
either in the carboxylic group or in the phenolic ring (Heleno et al., 2015). Cinnamic acid 261 
(CA) showed the highest anti-inflammatory activity presenting the lowest EC50 values (182 ± 262 
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16 µM), followed by p-hydroxybenzoic (239 ± 29 µM) and p-coumaric (442 ± 33 µM) acids. 263 
Cinnamic acid presents a carboxylic group and no OH groups in the benzene ring. p-264 
Hydroxybenzoic and p-coumaric acids present an OH group in the para position that is 265 
usually a position described as having biological properties. However, in the present study 266 
and comparing the activity exhibited by these three molecules, the OH group in the para 267 
position seems to decrease the anti-inflammatory ability, maybe due to the mechanism of 268 
action in this specific cell line. Several authors suggest that the anti-inflammatory activity is 269 
related with the ability of the compounds to inhibit the activity of the cyclooxygenase (COX) 270 
enzyme, which is responsible for the synthesis of prostaglandins, mediators with a great 271 
ability to induce inflammation (Lee et al., 2006; Tanaka et al., 2009). Studies on the 272 
mechanism of action of these molecules are important to better understand their behaviour. 273 
Nevertheless, these results are in agreement with the ones reported by our research group for 274 
the antimicrobial activity of these compounds, where cinnamic acid also revealed the 275 
strongest activity followed by p-hydroxybenzoic and p-coumaric acids (Heleno et al., 2014a).  276 
 277 
3.4. In vitro anti-inflammatory activity of glucuronated and methylated derivatives of the 278 
identified compounds 279 
As phenolic acids are metabolized in the organism and suffer conjugation reactions 280 
originating different metabolites such as glucuronated and methylated derivatives, a change 281 
in their effects or activity may also occur. Thus, the bioactivity of the parent molecule can be 282 
increased, decreased or maintained (Heleno et al., 2015). Hereby the glucuronated and 283 
methylated derivatives of the considered acids were analysed and compared to the one of the 284 
parent molecule. Among the glucuronated derivatives, CoA-GP (glucuronated derivative of 285 
p-coumaric acid) presented strong anti-inflammatory activity (58 ± 5 µM), being comparable 286 
to the activity of the standard dexamethaxone (40 ± 4 µM), followed by the glucuronated 287 
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derivatives of cinnamic (CA-GP) (179 ± 71 µM) and p-hydroxybenzoic (HA-GP) (1901 ± 288 
104 µM) acids. Contrarily to the results verified for the anti-inflammatory activity of the 289 
three parental molecules, the glucuronated derivative of p-coumaric acid exhibited the 290 
strongest activity, presenting an acetylated glucuronide in the carboxylic group and an OH 291 
group in the para position equal to the glucuronated derivative of p-hydroxybenzoic acid, 292 
but, with a double bond in the middle increasing the lateral chain. Thus, the strongest activity 293 
can be related with the double bound that stabilizes the molecule and the reactivity of the 294 
benzenic ring to be able to inhibit the activity of COX.  Regarding the methylated derivatives, 295 
those of p-coumaric acid presented higher activity than the ones of cinnamic or p-296 
hydroxybenzoic acids; in particular, the methylated derivative CoA-M1, with an ester instead 297 
of the carboxylic group, revealed very strong activity (35 ± 2 µM), very close to the 298 
dexamethaxone value (40 ± 4 µM). Also in the case of methylated derivatives it seems that 299 
the double bound of p-coumaric acid allows a higher ability to interact with the tested cell 300 
line, while in the case of p-hydroxybenzoic acid that has no double bound, the ester and OH 301 
groups are more close to each other and can chemically interact changing the molecule 302 
stability and decreasing the bioactivity. 303 
Comparing the activity of each parent molecule and the corresponding glucuronated and 304 
methylated derivatives, the order was as follows: p-hydroxybenzoic acid: HA > HA-M3 > 305 
HA-M2 >HA-M1 > HA-GP; p-coumaric acid: CoA-M1 > CoA-GP > CoA-M2 > CoA-M3 > 306 
CoA; and cinnamic acid: CA-GP > CA > CA-M. p-Hydroxybenzoic acid showed higher 307 
activity than the corresponding derivatives, with HA-M3 as the most active compound; the 308 
decreased anti-inflammatory activity observed for HA-M1, HA-M2 and HA-GP could be 309 
explained by the esterification of the carboxylic group. On the contrary, all p-coumaric acid 310 
derivatives showed higher activity than the parent molecule (CoA), particularly the 311 
methylated compound CoA-M1, suggesting that in this case the esterification of the 312 
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carboxylic group together with the free OH group in para position increased their anti-313 
inflammatory activity. The glucuronated derivative of cinnamic acid (CA-GP) maintained its 314 
activity in comparison with the parent molecule (CA), while the methylated one (CA-M) 315 
decreased it. 316 
These results are in relatively good agreement with the ones previously reported by our 317 
research group comparing the antimicrobial activity of p-hydroxybenzoic, p-coumaric and 318 
cinnamic acids and their respective methylated and glucuronated derivatives. The 319 
methylation of p-hydroxybenzoic and cinnamic acids decreased the antimicrobial activity, 320 
while the methylation of p-coumaric acid increased it (Heleno et al., 2014a); moreover, the 321 
glucuronidation of the parent molecules also decreased the antimicrobial activity, except for 322 
HA-GP that showed higher antifungal activity against some pathogenic strains (Heleno et al., 323 
2013a). 324 
 325 
4. Conclusion 326 
Overall, the mushroom species: P. ostreatus, M. procera, B. impolitus and A. bisporus 327 
revealed the strongest anti-inflammatory potential presenting the highest inhibition of NO 328 
production. These mushroom species also revealed the highest concentration in cinnamic 329 
acid, which was also the individual compound that presented the strongest anti-inflammatory 330 
activity and, therefore, could play an important role in the observed activity.  However, the 331 
conjugation reactions occurring in the organism can change the chemical structure of 332 
cinnamic and phenolic acids increasing or decreasing their in vivo anti-inflammatory activity. 333 
The possible metabolites previously synthesised by the authors and tested in the present work 334 
are still displaying activity, in some cases like CoA-GP and CoA-M1 higher than the parent 335 
compound and very close to the activity exhibited by dexamethaxone used as anti-336 
inflammatory standard.  337 
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Table 1. Some previous studies on anti-inflammatory activity of different mushroom species 
evaluated through NO assay. 
 
Species Country Extract Inhibition of NO production  References 
Spain Methanol 
 
30% at 0.5 mg/mL Moro et al., 2012 Agaricus 
bisporus 
Australia  Ethanol 50% at 0.032 mg/mL 
 
Gunawardena et al., 2014 
Boletus edulis Spain  Methanol 10% at 0.5 mg/mL Moro et al., 2012 
Cantharellus 
cibarius 
Spain  Methanol 70% at 0.5 mg/mL Moro et al., 2012 
Caripia 
montagnei 
Brazil  Acetone 80%, 
methanol 
43% at 10 mg/kg  
54% at 30 mg/kg  
49% at 50 mg/kg 
Queiroz et al., 2010 
Cratarellus 
cornucopoides 
Spain  Methanol 55% at 0.5 mg/mL Moro et al., 2012 
Flammulina 
velutipes 
Australia Ethanol 50% at 0.024 mg/mL Gunawardena et al., 2014 
China  Ethanol  65% at 40 µg/mL Ma et al., 2013 Inonotus 
obliquus South Korea  Ethanol  50% at 89 µg/mL Park et al., 2005 
Lactarius 
deliciosus 
Spain  Methanol 40% at 0.5 mg/mL Moro et al., 2012 
Lentinus 
edodes 
Australia  Ethanol 50% at 0.027 mg/mL Gunawardena et al., 2014 
Australia  Ethanol 50% at 0.077 mg/mL Gunawardena et al., 2014 Pleurotus 
ostreatus 
 
Spain  Methanol  15% at 0.5 mg/mL Moro et al., 2012 
Pleurotus 
tuber-regium 
Belgium  Ethanol 70% at 0.5 mg/mL Liu et al., 2014 
Tricholoma 
matsutake  
South Korea  Dichloromethane 47% at 2 mg/mL  Lim et al., 2007 
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Table 2. Cinnamic and phenolic acids identified and quantified by HPLC-PDA in the 
ethanolic extracts of the analysed mushrooms. 
 
Mushroom  
species 
Extraction 
yield (%) 
p-Hydroxybenzoic 
acid  (µg/g) 
p-Coumaric 
acid (µg/g) 
Cinnamic 
acid (µg/g) 
Agaricus bisporus 6.9 ± 0.7abcd nd nd 149 ± 2d 
Agaricus  
bisporus  Portobello 
6.0 ± 0.1bcd nd nd 11 ± 1hi 
Amanita caesaria 5.4 ± 0.5cd 57 ± 3e nd 156 ± 3d 
Boletus aereus 7.7 ± 0.6abc 43 ± 1f 74 ± 1b 50 ± 3f 
Boletus edulis 10.4 ± 0.5ª nd nd 14.2 ± 0.4gh 
Boletus flagrans 4.9 ± 0.3cd nd nd 6.1 ± 0.3i 
Boletus impolitus 4.1 ± 0.5d 125 ± 9c 45 ± 2c 505 ± 12c 
Boletus reticulatus 9.5 ± 0.3ab nd nd 20.3 ± 0.1g 
Cantharellus cibarius 4.0 ± 0.3d 151 ± 2b nd 71 ± 1e 
Lactarius deliciosus 3.7 ± 0.4d 108 ± 5d nd 67 ± 1e 
Morchella esculenta 4.0 ± 0.8d nd nd 71 ± 3e 
Macrolepiota procera 3.7 ± 0.4d nd nd 522 ± 1b 
Pleurotus eryngii 10.1 ± 0.6a nd nd 16 ± 1gh 
Pleurotus ostreatus 4.0 ± 0.6d 297 ± 5a 171 ± 1a 619 ± 3a 
nd- not detected. ANOVA In each column, different letters mean statistical significant 
differences (p<0.05) between samples. 
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Table 3. Extract concentrations responsible for 50% of reduction of NO production (EC50 
values) in RAW 264.7 cell line. 
 
EC50 values correspond to 50% of inhibition of the NO production in comparison with the 
negative control (100% of NO production). In the columns, different letters mean statistical 
significant differences (p<0.05) between samples. Dexamethaxone EC50 value = 16 ± 2 
µg/mL.   
 
Mushroom species EC50 values (µg/mL) Mushroom species EC50 values (µg/mL) 
Agaricus bisporus 190 ± 6ef Boletus reticulatus 378 ± 28ab 
Agaricus bisporus 
portobelo 
>400ª Cantharellus cibarius 202 ± 17e 
Amanita caesaria  186 ± 7ef Lactarius deliciosus 253 ± 14d 
Boletus aereus 357 ± 3b Macrolepiota procera 162 ± 2g 
Boletus edulis >400ª Morchella esculenta 287 ± 9c 
Boletus flagrans >400ª Pleurotus eryngii 388 ± 17a 
Boletus impolitus 166 ± 10fg Pleurotus ostreatus 96 ± 1h 
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Table 4. Concentrations of the studied acids and their glucuronated and methylated 
derivatives responsible for 50% of reduction of NO production (EC50 values, µM) in RAW 
264.7 cell line. 
 
p-Hydroxybenzoic acid and 
derivatives 
p-Coumaric acid and 
derivatives 
Cinnamic acid and 
derivatives 
HA 239 ± 29c CoA 442 ± 33a CA 
HA-GP 1901 ± 104a CoA-GP 58 ± 5c CA-GP 
HA-M1 1825 ± 120a CoA-M1 35 ± 2c CA-M 
182 ± 16b 
179 ± 17b 
224 ± 16a 
HA-M2 526  ± 26b CoA-M2 128 ± 10b   
HA-M3 509 ± 47b CoA-M3 129 ± 6b   
   
EC50 values correspond to 50% of inhibition of the NO production in comparison with the 
negative control (100% of NO production). In each column, different letters mean statistical 
significant differences (p<0.05) between compounds. Dexamethaxone EC50 value = 40 ± 4 
µM. 
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Figure 1. Synthesis of methylated and glucuronated derivatives of p-hydroxybenzoic, p-
coumaric and cinnamic acids. A) i) Glucuronidation of cinnamic acid (CA). CA-GP- cinnamic acid 
glucuronide protected form, 2,3,4-tri-O-acetyl-1-cinnamoyl-D-glucuronic acid methyl ester (Heleno et 
al., 2013a); ii) Methylation of CA. CAM- methyl 3-phenylacrylate (Heleno et al., 2014b). B) i) 
Glucuronidation of p-coumaric acid (CoA). CoA-GP- p-Coumaric acid glucuronide protected form, 
2,3,4-tri-O-acetyl-1-p-coumaroyl-D-glucuronic acid methyl ester (Heleno et al., 2014b); ii)-iv) 
Methylations of CoA. CoA-M1- 3-(4-hydroxyphenyl) acrylate, CoA-M2- methyl-(4-methoxyphenyl) 
acrylate, CoA-M3- 3-(4-methoxyphenyl) acrylic acid (Heleno et al. 2014b). C) i) Glucuronidation of 
p-hydroxybenzoic acid (HA). HA-GP- p-hydroxybenzoic acid protected form, 2,3,4-tri-O-acetyl-1-p-
hydroxybenzoyl-D-glucuronic acid methyl ester (Heleno et al., 2013a); ii-iv) Methylations of p-
hydroxybenzoic acid, HA-M1- methyl 4-hydroxybenzoate, HA-M2- methyl-p-anisate, HA-M3- 4-
methoxybenzoic acid (Heleno et al., 2014b). 
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Figure 2. Effects of the ethanolic mushroom extracts in the NO produced by RAW 
264.7 cell line. Mean values and standard errors, expressed in relation to the negative 
control (without extract)- 100% of production. 0 µg/mL; 50 µg/mL; 100 
µg/mL; 200 µg/mL; 400 µg/mL. 
 
 
 
